My watch list
my.bionity.com  
Login  

Novo Nordisk completes divestment of ZymoGenetics, Inc.

13-Oct-2010

Bristol-Myers Squibb Company and ZymoGenetics, Inc. have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for USD 9.75 per share in cash. Novo Nordisk has been a shareholder of ZymoGenetics since 1988 and at the time of the transaction, Novo Nordisk owned 22,143,320 shares, equalling close to 26% of the share capital. Pursuant to an agreement between the companies, Novo Nordisk has tendered all of its shares to Bristol-Myers Squibb. The transaction was subject to a number of conditions. All conditions have now been fulfilled or waived and thus Novo Nordisk’s divestment was completed.

As a consequence of this transaction, Novo Nordisk expects to record a nonrecurring income of approximately DKK 1.1 billion in relation to the sale of its shares in ZymoGenetics, which will be recorded under ‘Share of profit in associated companies’ in the ‘Net financials’ part of the income statement for 2010. The income from the transaction is exempt from tax charges under applicable Danish tax laws and is expected to have a positive non-recurring effect on the effective tax rate for the group in 2010 of approximately 1.5 percentage points.

Facts, background information, dossiers
  • Novo Nordisk
  • ZymoGenetics
  • Bristol-Myers Squibb
More about Novo Nordisk
More about Bristol-Myers Squibb
More about ZymoGenetics
  • News

    Novo Nordisk divests its ownership of ZymoGenetics, Inc.

    Bristol-Myers Squibb Company and ZymoGenetics, Inc. have announced the signing of a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for USD 9.75 per share in cash. The transaction has been unanimously approved by the Boards of Directors of both com ... more

    Dyax and ZymoGenetics Enter Into Library License Agreement for Discovery of Therapeutic Antibodies

    Dyax Corp. announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to ZymoGenetics, Inc. for the discovery of therapeutic antibodies. This collaboration with ZymoGenetics is part of Dyax's Licensing and Funded Research Program (LFRP) partner ... more

  • Companies

    ZymoGenetics, Inc.

    ZymoGenetics is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human disease. Thanks to a robust discovery program, promising drug pipeline and strong development capabilities, ZymoGenetics is an emerging leader among bi ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE